Analytical Data
-
基因名
HLA-A*11:01&B2M&EBV LMP2(SSCSSCPLSK) Monomer
- Application
-
别名
HLA-A*1101 & B2M & EBV LMP2 (SSCSSCPLSK)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAV53343.1 (G25-T305)&P61769
-
表达区间
AAV53343.1 (G25-T305)&P61769 (I21-M119)&SSCSSCPLSK
-
分子量
40-43 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of HLA-A*11:01, Beta-2-Microglobulin (B2M), and the Epstein-Barr Virus (EBV) LMP2 peptide (SSCSSCPLSK) monomeric recombinant protein is driven by the need to understand the immune response to EBV, a virus associated with various malignancies and autoimmune diseases. HLA-A*11:01 is a class I major histocompatibility complex (MHC) molecule critical for presenting viral antigens to CD8+ cytotoxic T cells, thereby initiating an adaptive immune response. The LMP2 protein, derived from EBV, plays a pivotal role in viral latency and immune evasion. Investigating the interaction between HLA-A*11:01 and the EBV LMP2 peptide offers insights into how the virus eludes immune detection and contributes to pathogenesis. The recombinant production of this protein allows for detailed structural and functional analyses, including binding affinity studies and T cell activation assays, which can elucidate the specificity of T cell responses and the potential for developing targeted immunotherapies. Additionally, this research has implications for vaccine development against EBV and provides a framework for understanding MHC-peptide interactions in the context of viral infections, paving the way for novel strategies to enhance immune recognition and clearance of EBV-associated diseases. Understanding these interactions is critical for harnessing the immune system's power, potentially leading to advancements in treatment and prevention strategies against EBV-related health issues.
